Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31142174 | 0.93 | GSK3A (0.56) | GSK3AGSK3BMEN1TSHRKMT2A | |
| SCHEMBL4351612 | 0.80 | TDP1 (0.66) | MEN1KMT2ACYP1A2CYP2C19TDP1 | |
| SCHEMBL6790333 | 0.76 | TDP1 (0.71) | MEN1KMT2ACYP1A2CYP2C19TDP1 | |
| SCHEMBL14077581 | 0.75 | MAOB (0.52) | MAOBHTR1A | |
| SCHEMBL6777483 | 0.74 | TDP1 (0.75) | MEN1KMT2ACYP1A2CYP2C19TDP1 | |
| SCHEMBL8863154 | 0.74 | TDP1 (0.75) | MEN1KMT2ACYP1A2CYP2C19TDP1 | |
| SCHEMBL2604742 | 0.74 | TDP1 (0.75) | MEN1KMT2ACYP1A2CYP2C19TDP1 | |
| SCHEMBL8862878 | 0.74 | TDP1 (0.75) | MEN1KMT2ACYP1A2CYP2C19TDP1 | |
| SCHEMBL8862728 | 0.74 | TDP1 (0.75) | MEN1KMT2ACYP1A2CYP2C19TDP1 | |
| SCHEMBL8863094 | 0.74 | TDP1 (0.75) | MEN1KMT2ACYP1A2CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12150935-B1 | 3-(3-(1,3-dioxoisoindolin-2-yl) propyl)-5-(4-fluorobenzylidene) thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer | IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) | 2024-11-26 | — | — | US | claimed |
| US-12150935-B1 | 3-(3-(1,3-dioxoisoindolin-2-yl) propyl)-5-(4-fluorobenzylidene) thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer | IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) | 2024-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12150935-B1 | 3-(3-(1,3-dioxoisoindolin-2-yl) propyl)-5-(4-fluorobenzylidene) thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer | MCL1, CASP3, ACIN1 | GSK3A 3415/4885GSK3B 3163/4885MAOB 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.